日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial

一项多中心、随机、双盲、安慰剂对照的3期临床试验:在初诊晚期卵巢癌患者中,使用氟哌啶醇联合或不联合阿帕替尼作为维持治疗方案的疗效评价(FZOCUS-1):一项多中心、随机、双盲、安慰剂对照试验

Wu, Lingying; Wang, Jing; Li, Qingshui; Wang, Danbo; Zhang, Cuiying; Tang, Junying; Zhang, Guonan; Hao, Min; Yao, Desheng; Gao, Qinglei; Zhang, Youzhong; An, Ruifang; Yin, Rutie; Wang, Li; Xia, Bairong; Zhou, Qi; Yang, Hongying; Zhu, Jianqing; Jiang, Kui; Chen, Zhengzheng; Wu, Qiang; Duan, Wei; Huang, Yi; Zhang, Hui; Wei, Shuqing; Li, Guiling; Meng, Yuanguang; Wang, Ke; Yang, Xinfeng; Huang, Xianghua; Pan, Lingya; Yu, Jinjin; Lou, Ge; Zhang, Yu; Zhou, Huaijun; Guo, Xiaoqing; Yang, Hong; Cheng, Xiaodong; Li, Xiumin; Wang, Wuliang; Zhao, Hongqin; Li, Yunxia; Yang, Yingjie; Lin, An; Cheng, Wenjun; Chen, Lihong; Xie, Xiaoying; Di, Wen; Hu, Yuanjing; Chen, Mo; Wen, Hongwu; Cai, Liping; Wu, Xiaohua; Lin, Zhongqiu; Wang, Quanren; Yang, Xinfeng; Li, Ning

Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancreatic ductal adenocarcinoma

HR070803(伊立替康脂质体)联合5-氟尿嘧啶、亚叶酸钙和奥沙利铂治疗未经治疗的晚期或转移性胰腺导管腺癌的I期临床试验

Xu, Qiang; Zhao, Xue; Wang, Xianze; Zhu, Ruizhe; Cheng, Yuejuan; Xia, Tao; Wu, Heshui; Tian, He; Sun, Yuping; Zhang, Mingjun; Gao, Chuntao; Fu, Deliang; Wu, Xiaojie; Zheng, Tongsen; Yin, Xiaoyu; Chen, Yili; Chen, Xiaobing; Li, Zhihua; Chen, Rufu; Yang, Xue; Wang, Huan; Wang, Quanren; Han, Xiaohong; Wu, Wenming

A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer

一项随机、开放标签、多中心、活性对照的II期研究,比较改良制剂醋酸阿比特龙片(II)与原研醋酸阿比特龙在转移性去势抵抗性前列腺癌患者中的疗效。

Lu, Xiaolin; Dai, Tao; Chen, Xue; Wu, Bin; Chen, Hui; Wu, Jitao; Yu, Dexin; Ge, Huixin; Li, Jian; Huang, Houbao; Fan, Tiwu; Cheng, Linzhong; Zhang, Xiaoping; Zhang, Xuepei; Yao, Xin; Wei, Junli; Xu, Zhenqiang; Yang, Wenzeng; He, Chaohong; Luo, Jiexin; Guan, Ling; Fu, Bin; Wang, Qilin; Chen, Xiaofeng; Zhang, Yongdong; Shi, Benkang; Zheng, Bin; Wang, Yong; Luo, Hong; Chen, Guoqiang; Wang, Huan; Wang, Quanren; Ye, Dingwei

Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study

HRS-1780在肾功能不全患者中的药代动力学和安全性:一项多中心、非随机、开放标签研究

Fei, Yue; Xie, Zhihong; Luo, Yuanyuan; Yong, Xiaolan; Li, Na; Huang, Rong; Du, Xiaolin; Zhu, Yijing; Lan, Dongmei; Qi, Yang; Cheng, Gang; Wang, Quanren; Shen, Kai

Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial

伊立替康盐酸盐脂质体 HR070803 联合 5-氟尿嘧啶和亚叶酸钙治疗既往接受过吉西他滨治疗的局部晚期或转移性胰腺导管腺癌(PAN-HEROIC-1):一项 3 期试验

Cui, Jiujie; Qin, Shukui; Zhou, Yuhong; Zhang, Shuang; Sun, Xiaofeng; Zhang, Mingjun; Cui, Jiuwei; Fang, Weijia; Gu, Kangsheng; Li, Zhihua; Wang, Jufeng; Chen, Xiaobing; Yao, Jun; Zhou, Jun; Wang, Gang; Bai, Yuxian; Xiao, Juxiang; Qiu, Wensheng; Wang, Bangmao; Xia, Tao; Wang, Chunyue; Kong, Li; Yin, Jiajun; Zhang, Tao; Shen, Xionghu; Fu, Deliang; Gao, Chuntao; Wang, Huan; Wang, Quanren; Wang, Liwei

Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: two randomized, double-blind, single-ascending-dose, phase 1 studies

在健康成年受试者中单次静脉注射SHR-1707的安全性、耐受性、药代动力学和药效学:两项随机、双盲、单次递增剂量I期研究

Yang, Yaru; Qiu, Hongyan; Fan, Yuru; Zhang, Qin; Qin, Huiling; Wu, Juan; Zhang, Xuan; Liu, Yueyue; Zhou, Renpeng; Zhang, Qian; Ye, Zi; Ma, Jingyue; Xu, Ye; Feng, Sheng; Fei, Yue; Li, Na; Cui, Xiaojing; Dong, Fangli; Wang, Quanren; Shen, Kai; Shakib, Sepehr; Williams, Jasmine; Hu, Wei

A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting anti-thymic stromal lymphopoietin antibody, in healthy subjects

一项 I 期随机、双盲、安慰剂对照、剂量递增研究,旨在评估长效抗胸腺基质淋巴细胞生成素抗体 SHR-1905 在健康受试者中的安全性、耐受性、药代动力学和免疫原性。

Fei, Yue; Li, Na; Qian, Weilin; Fan, Yang; Shen, Yu; Wang, Quanren; McLendon, Kristi; Shen, Kai

Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial

奥替康唑与氟康唑治疗重度外阴阴道念珠菌病:一项多中心、随机、双盲、3期临床试验

Wang, Xiaoqian; Chen, Lihong; Ruan, Hongjie; Xiong, Zhengai; Wang, Wenying; Qiu, Jin; Song, Weihua; Zhang, Chunlian; Xue, Fengxia; Qin, Tianhua; Zhang, Bei; An, Ruifang; Luo, Xiping; Wang, Wei; Zhang, Songling; Cai, Yunlang; Kang, Jiali; Deng, Henan; Fan, Shangrong; Cui, Manhua; Wang, Shijin; Luo, Xiaowan; Su, Zhiying; Shu, Jing; Wang, Quanren; Wang, Fang; Bai, Jianling; Liao, Qinping

Safety and efficacy of a novel dexmedetomidine nasal spray for pre-anesthetic sedation in children: a randomized, double-blind, placebo-controlled trial

一种新型右美托咪定鼻喷雾剂用于儿童麻醉前镇静的安全性和有效性:一项随机、双盲、安慰剂对照试验

Gao, Jia; Wang, Fang; Wang, Xiaoling; Zou, Xiaohua; Liu, Hua-Cheng; Song, Xingrong; Chai, Xiaoqing; Jiang, Rong; Zhao, Ping; Zhang, Jiaqiang; Wang, Sai-Ying; Ma, Haichun; Zhao, Zhibin; Wang, Quanren; Zhou, Na; Bai, Jianling; Zhang, Jianmin

A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis

一项评估氟哌啶醇联合阿帕替尼治疗晚期卵巢癌和三阴性乳腺癌的I期临床试验:疗效、安全性、药代动力学和生殖系BRCA突变分析

Liu, Yaxin; Wang, Wei; Yin, Rutie; Zhang, Youzhong; Zhang, Yu; Zhang, Keqiang; Pan, Hongming; Wang, Ke; Lou, Ge; Li, Guiling; Zhang, Ruyan; Li, Kun; Rao, Jing; Zhang, Ben; Wang, Yuting; Wang, Quanren; Gao, Yunong; Li, Huiping